

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Lee's Pharmaceutical Holdings Limited

李氏大藥廠控股有限公司*

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 950)

INSIDE INFORMATION DISPOSAL OF SHARES BY SUBSTANTIAL SHAREHOLDER

This announcement is made by Lee's Pharmaceutical Holdings Limited (the "**Company**") pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**") and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The Company was informed by Essetifin S.p.A., a substantial shareholder of the Company holding 142,053,333 shares of the Company (the "**Shares**") (representing approximately 24.07% of the total issued share capital of the Company) that, on 31 March 2017 (after trading hours), it has (a) disposed of 39,339,935 Shares (representing approximately 6.66% of the total issued share capital of the Company) at HK\$6.80 per Share to a fund (the "**Fund**"); (b) disposed of 17,000,000 Shares (representing approximately 2.88% of the total issued share capital of the Company) at HK\$6.80 per Share to another existing substantial shareholder of the Company (the "**Existing Substantial Shareholder**"); and (c) disposed of 28,892,000 Shares (representing approximately 4.90% of the total issued share capital of the Company) at HK\$6.80 per Share to certain other parties (the "**Other Purchasers**") (the "**Disposal**").

To the best of the knowledge, information and belief of the directors of the Company (the "**Director**") having made all reasonable enquiry, (a) Dr. Li Xiaoyi, an executive Director, is a limited partner holding approximately 5.71% of the total investment in the Fund; (b) the Existing Substantial Shareholder is an existing substantial shareholder of the Company, which is not a Director; and (c) the Other Purchasers are independent of and not connected with the Company and its connected persons (as defined in the Listing Rules).

Immediately after the Disposal, the shareholding of Essetifin S.p.A. in the Company decreased from approximately 24.07% to approximately 9.63%.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company.

By order of the Board
Lee's Pharmaceutical Holdings Limited
Lee Siu Fong
Chairman

Hong Kong, 3 April 2017

** For identification purpose only*

As at the date of this announcement, Ms. Lee Siu Fong (Chairman), Ms. Leelalertsuphakun Wanee and Dr. Li Xiaoyi are executive Directors, Dr. Marco Maria Brughera is a non-executive Director, Dr. Chan Yau Ching, Bob, Mr. Lam Yat Cheong and Dr. Tsim Wah Keung, Karl are independent non-executive Directors.